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 Abstract: 
Myelin is essential for the mammalian brain to function efficiently. Whilst many factors have 
been associated with regulating the differentiation of oligodendroglia and myelination, 
glutamate signalling might be particularly important for learning-dependent myelination. The 
majority of myelinated projection neurons are glutamatergic. Oligodendrocyte precursor cells 
receive glutamatergic synaptic inputs from unmyelinated axons and oligodendrocyte lineage 
cells express glutamate receptors which enable them to monitor and respond to changes in 
neuronal activity. Yet, what role glutamate plays for oligodendroglia is not fully understood. 
Here, we review glutamate signalling and its effects on  oligodendrocyte lineage cells,and 
myelination  in health and disease. Furthermore, we discuss whether glutamate signalling 
between neurons and oligodendroglia might lay the foundation to activity-dependent white 
matter plasticity.  
  
*Abstract
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Introduction  
Myelin, produced by oligodendrocytes in the central nervous system (CNS), is essential for rapid 
information transmission and synchronisation of inputs between billions of neurons. Myelin plasticity, 
which has been largely neglected, is now increasingly invoked as a fundamental mechanism for 
learning (see Purger et al., 2016 and Tomlinson et al, 2016 in this issue). Myelination has been shown 
to be orchestrated by a plethora of cellular and molecular signals, including axonal diameter, growth 
factors, extracellular signalling factors, secreted molecules and adhesion proteins, neurotransmitter 
signalling and neuronal activity (reviewed by Emery, 2010). The latter two might be of particular 
importance for myelin plasticity, especially glutamate signalling as 90% of projection neurons, and 
thus the majority of myelinated axons in the CNS, are glutamatergic (Schmidt and Pierce, 2010) and 
oligodendrocyte lineage cells, at all stages, express glutamate receptors, enabling them to sense and 
respond to neuronal activity.  
 
Here we will review how glutamate, a universal signalling molecule, can mediate seemingly unrelated 
processes such as migration, proliferation, differentiation and myelination, as well as cellular death, 
and regeneration.  
 
Synaptic and non-synaptic glutamate signalling  
Glutamate is the most common excitatory neurotransmitter in the CNS (see Box 1). This non-essential 
amino acid has a myriad of functions across species, both in and outside the CNS (see Box 2). In the 
CNS, glutamate signalling is commonly associated with synaptic transmission. The synapse, defined 
by a presynaptic and a postsynaptic site separated by the synaptic cleft (Palay, 1958), is the primary 
neuronal information hub. At glutamatergic synapses, the presynaptic machinery (which includes the 
canonical SNARE complex) releases glutamate through calcium- and activity-dependent vesicular 
release. The majority (90%) of synaptic transmission occurs in this fashion (Kaeser and Regehr, 
2014), and thus can be named canonical glutamate release to distinguish it from other forms of 
vesicular release that also occur at the presynaptic terminal, such as spontaneous and asynchronous 
synaptic transmission (Kavalali, 2015; Kaeser and Regehr, 2014; see Figure 1), which can occur in 
activity-, calcium- and canonical SNARE independent manner.  
 
Although widespread, glutamate release is not confined to the synapse. It can also occur outside the 
synapse by non-vesicular release of glutamate (occurring either in an activity-dependent or 
-independent manner) as well as by vesicular release (occurring either in an activity-dependent or 
-independent manner; Ziv and Garner, 2004; see Figure 1). The regulation and role of the varied 
forms of non-synaptic glutamate release are less known. Nonetheless, non-synaptic release of 
*Manuscript
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neurotransmitter seems to play an important role early in development, particularly as the expression 
of functional glutamatergic (and GABAergic) receptors precedes synaptogenesis (Andreae and 
Burrone, 2015; Ziv and Garner, 2004; Demarque et al., 2002; Furuta et al., 1997). Possible sources of 
non-synaptic glutamate release are from the reversal of glutamate transporters (Káradóttir and 
Attwell, 2007) and the release from neuronal growth cones (Soeda et al., 1997), astrocytes (reviewed 
by Malarkey et al., 2008), microglia (Barger et al., 2007), or from damaged or dying cells (see Figure 
1). Whether this non-synaptic form of communication serves a different purpose than synaptic 
transmission, remains to be investigated. However, as non-synaptic glutamate signalling is used by 
cells in many different tissues and throughout life, it might serve an equally important but lesser 
known function (see Box 2).  
 
Throughout this review we use the term 'synaptic release' to refer to activity- and canonical SNARE-
dependent vesicular release of glutamate, and 'non-synaptic release' for glutamate release that occurs 
outside the synapse (not differentiating between vesicular and non-vesicular non-synaptic release). 
We have omitted postulating the function of spontaneous, activity- and canonical SNARE-
independent vesicular release at the axon-OPC synapse due to lack of information in the literature, 
although spontaneous TTX insensitive miniature events have been detected in OPCs (Káradóttir et al., 
2005; 2008; Bergles et al., 2000; Ziskin et al, 2007; Kukley et al. 2007).  
 
Oligodendroglia receive glutamatergic input 
The presence of glutamate receptors in the oligodendroglial cell membrane throughout the lineage 
suggests that glutamate signalling is important for these cells both during their progenitor and their 
mature stage. Oligodendrocyte precursor cells (OPCs) in particular are well equipped to sense 
neuronal activity. They express the highest density of glutamate receptors compared to later lineage 
stages (De Biase et al., 2010) and receive synaptic input from neurons in both grey (Bergles et al., 
2000; Jabs et al., 2005; Lin and Bergles, 2004) and white matter (Káradóttir et al., 2005, 2008; Kukley 
et al., 2007; Ziskin et al., 2007). These synaptic contacts seem to occur predominantly on entirely 
unmyelinated axons or unmyelinated segments of the axon (Kukley et al., 2007; Tomassy et al., 2014; 
Ziskin et al., 2007), which raises the question of whether synaptic input is involved in prompting OPC 
differentiation and myelination.  
 
It is generally assumed that synaptic input is restricted to the progenitor state of oligodendroglia and 
disappears once differentiation begins (De Biase et al., 2010; Kukley et al., 2007), although 
oligodendrocytes express glutamate receptors throughout all lineage stages (Butt, 2006; Káradóttir et 
al., 2005; Lundgaard et al., 2013; Micu et al., 2006; Salter and Fern, 2005; but see Kukley et al., 2010; 
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see Table 1). Perhaps non-synaptic glutamate signalling becomes more important for differentiated 
oligodendrocytes (see Figure 1).  
 
Myelinating oligodendrocytes respond to neuronal activity (Fröhlich et al., 2014; Yamazaki et al., 
2010), likely via an NMDA receptor-mediated calcium rise in the myelin sheath (Micu et al., 2016). 
Thus, glutamate signalling might in fact be ongoing between axons and oligodendrocytes throughout 
life. Micu and colleagues coined the concept of axo-myelinic synapses to describe activity-dependent 
vesicular release of glutamate from the axon to the oligodendrocyte (Micu et al., 2016).  
Whether myelinating oligodendrocytes do receive synaptic input is still uncertain. It is possible that 
they have gone unnoticed due to the large membrane capacitance of mature oligodendrocytes (that 
could mask the detection of synaptic input during electrophysiological recordings). 
 
Currently neither the role of synaptic input to OPCs nor the role of glutamate signalling to mature 
oligodendrocytes is fully understood. Below, we will review what is currently known about the effects 
of glutamate on oligodendroglial cells.  
 
Glutamate and OPC migration  
Before differentiating, OPCs form a dense network that spans the entire brain. Characteristically, 
OPCs are motile cells which can migrate long distances and continuously survey their environment 
via extended filopodia (Hughes et al., 2013). The activation of both AMPA/kainate and NMDA 
receptors in OPCs has been shown to increase motility through the modulation of the adhesion 
molecule PSA-NCAM (Wang et al., 1996) or the modification of Tiam1 signalling, which induces 
lamellipodium growth of leading OPC processes (Xiao et al., 2013). AMPA/kainate receptor 
activation also leads to the composition of an Dv-integrin and proteolipid protein (PLP) complex 
which associates with the AMPA receptor subunit GluA2 – a subunit which makes AMPA receptors 
impermeable to calcium (Gudz et al., 2006; see Figure 2). This leads to a reduction of GluA2 levels on 
the membrane, allowing for increased calcium conductance via AMPA receptors. This weakens OPC 
binding to the extracellular matrix and augments their migration rate (Gudz et al., 2006; Harlow et al., 
2015). However, blocking axonal activity-dependent vesicular release in vivo has no effect on OPC 
migration (Hines et al., 2015; Mensch et al., 2015). These conflicting results might reflect differences 
between neonatal (OPCs in vitro) and postnatal OPCs (OPCs in vivo). Synaptic inputs could only be 
detected in OPCs after postnatal day 5 (P5) (Ziskin et al., 2007), although OPCs express glutamate 
receptors from birth (Káradóttir and Attwell, 2007). Hence, it is possible that neonatal OPC migration 
is guided by non-synaptic glutamate signalling, which might serve as a long-range cue to guide OPC 
migration towards an axonal target. Non-synaptic glutamate signalling is known to act as a long-range 
signal for other cell types. It leads migratory hippocampal pyramidal neurons and interneurons 
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towards their target location during early development (Manent et al., 2005, 2006) and helps shaping 
the dendritic arbor guiding post-synaptic terminals toward the presynapse (Andreae and Burrone, 
2015; see also Box 2). Once an OPC associates with a target axon, synapses are presumably formed, 
which might function to fine-tune OPC localisation, adjust their surveying behaviour and guide their 
choice as to which axon to myelinate.  
 
The source of the non-synaptic glutamate can currently only be speculated upon. In neurons, 
glutamate can be released non-synaptically through the reversal of glutamate transporters (Káradóttir 
and Attwell, 2007). The axons of retinal ganglion cells, for example, release glutamate in this way 
during early development - a mechanism that is lost once myelination is underway (Kriegler and 
Chiu, 1993). Glutamate can also be released from axons prior to synaptogenesis either by activity-
dependent vesicular release or by spontaneous vesicular fusion, which is independent of neuronal 
activity and becomes almost undetectable once synapses are formed (Andreae and Burrone, 2015; see 
Figure 1).  
 
Glutamate and OPC proliferation  
Proliferation is an important feature of OPCs, which ensures the preservation of the progenitor pool 
and makes sure that demands can be met when cells differentiate in order to myelinate. The majority 
of studies using OPCs in vitro (Gallo et al., 1996) or cultured brain slices (Fannon et al., 2015; Yuan 
et al., 1998) have shown that activation of AMPA/kainate receptors inhibits OPC proliferation. 
However, glutamate enhances proliferation of OPCs derived from neuronal progenitors of the striatum 
or the SVZ (Brazel et al., 2005; Redondo et al., 2007), perhaps indicating that the effect of glutamate 
may be dependent on the developmental origins of the OPCs. Nevertheless, experiments using 
primary cortical OPC cultures demonstrate that sodium influx, through activated AMPA/kainate 
receptors, blocks delayed outward-rectifying potassium channels (Borges et al., 1994). Expression of 
these potassium channels is enhanced by the mitogen platelet-derived growth factor (PDGF)-Rα 
signalling and are exclusively expressed during the progenitor stage of oligodendrocyte lineage cells 
(Borges et al., 1994; Chittajallu et al., 2005; Hossain et al., 2014; Larson et al., 2015). Thus, glutamate 
can reversibly reduce the proliferative effects of PDGF by blocking outward potassium conductance 
(Borges et al., 1994; Chittajallu et al., 2005). It can therefore be hypothesised that glutamate may act 
as a stop-signal to pause proliferation as soon as OPCs reach their target neuron, where the axon-OPC 
synapse will be formed (see Figure 3A).  
 
In vivo, the role that glutamate, or neuronal activity, plays in OPC proliferation is somewhat more 
obscure. When whiskers are removed in mice, presumably leading to a loss of sensory input to the 
barrel cortex and consequently to the loss of synaptic input to OPCs, OPC proliferation increases 
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(Mangin et al., 2012). On the other hand, increasing neuronal activity in the adult mouse brain, either 
through optogenetic stimulation of cortical neurons (Gibson et al., 2014) or through the acquisition of 
new motor skills (McKenzie et al., 2014), which arguably increases neuronal glutamate release, OPC 
proliferation is enhanced, not decreased. Matters are further complicated by studies which fail to see 
any correlation between glutamatergic input and OPC proliferation. Reducing either neuronal activity, 
or specifically neuronal activity- and canonical SNARE-dependent vesicular release of glutamate 
seems to have no effect on OPC proliferation (Hines et al., 2015; Mensch et al., 2015). A possible 
explanation may be that increased neuronal activity increases differentiation of OPCs (see below), and 
the increased proliferation seen in vivo reflects a secondary effect in which enhanced OPC 
proliferation is the result of more cells differentiating. Hughes et al (2013) elegantly demonstrated that 
within the OPC network, neighbouring OPCs are quick to proliferate and replace differentiating OPCs 
in order to maintain the network. It is difficult to determine whether glutamate per se increases OPC 
proliferation in vivo or whether this increase in proliferation is only a secondary effect of increased 
differentiation. Direct activation of AMPA/kainate receptors may decrease the response of OPCs to 
mitogens such as PDGF-α (Borges et al., 1994; Chittajallu et al., 2005; Gallo et al., 1996), thereby 
modulating proliferation and keeping the OPC population alert to alterations in activity that might 
initiate their differentiation. Another explanation could be that the inhibiting effects glutamate was 
shown to have in vitro on OPC proliferation reflect behaviours of prenatal and early postnatal OPCs 
in vivo since synaptic input is only detected from P5 in OPCs (Ziskin et al, 2007, see above). Perhaps, 
very localised glutamate release confined to the axon-OPC synapse has different effects on OPC 
proliferation than non-synaptic release of glutamate.  
 
Glutamate and OPC differentiation  
The role neuronal activity may play in OPC differentiation, myelination and myelin plasticity in 
adulthood is one of the most exciting and rapidly developing research areas of myelin biology. 
Glutamate might be an important mediator of neuronal activity, but its effects on oligodendrocyte 
differentiation and myelination are poorly understood. Before glutamate was known to be the major 
neurotransmitter in the CNS (see Box 1), ultrastructural studies showed that myelin thickness 
correlates with the axonal calibre (Duncan, 1934). Axonal diameter exceeding a certain threshold 
seems to be sufficient to induce myelination, which can occur independently of axonal activity and 
glutamate signalling, as both nanofibres and fixed axons, when co-cultured with OPCs, become 
myelinated (Bechler et al., 2015; Lee et al., 2012a; Li et al., 2014). However, an increasing body of 
evidence shows that neuronal activity, presumably mediated by glutamate, can regulate the 
differentiation of oligodendroglia. These seemingly contradictory observations may not be 
incompatible, but merely reflect that myelination can be accomplished in two complementary ways: 
dependent and independent of axonal activity (Lundgaard et al., 2013). One of the key factors for 
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activity-dependent myelination, it seems, is glutamate. However, the role of glutamate receptors is 
complex and it is possible that metabotropic glutamate receptors (mGluRs), AMPA/kainate and 
NMDA receptors serve different functions in regulating differentiation and myelination (as well as in 
the homeostasis of oligodendrocytes in general).  
 
Activating OPC mGluRs prompts differentiation (Spampinato et al., 2014; Wake et al., 2011) and 
regulates AMPA receptor expression (Zonouzi et al., 2011) and calcium influx, mediated by 
ionotropic glutamate receptors (iGluRs). Calcium influx via iGluRs up-regulates the expression of 
immediate early genes (Gallo et al., 1996; Lundgaard et al., 2013; Pende et al., 1994), which are 
associated with the regulation of cell growth and differentiation (Herschman, 1991; McMahon and 
Monroe, 1992). Yet, glutamate, predominantly via AMPA/kainate receptors, inhibits OPC 
differentiation in vitro (Gallo et al., 1996) and similarly, in cerebellar slices, AMPA/kainate agonists 
reduce the number of mature oligodendrocytes in a concentration dependent manner (Yuan et al., 
1998). Vice versa, blocking either AMPA/kainate receptors or neuronal activity increases the number 
of CC1+ immature oligodendrocytes (Fannon et al., 2015), suggesting that glutamate, acting via 
AMPA/kainate receptors, curbs differentiation. Despite the increase of CC1+ cells, these cells failed to 
fully differentiate into myelin basic protein (MBP)-expressing mature oligodendrocytes (Fannon et 
al., 2015). Perhaps, AMPA/kainate receptor activation is needed to guide OPCs to their target axons, 
and prime them for ‘the differentiation signal’ thus, blocking AMPA/kainate receptors releases them 
to differentiate unspecifically as it does not seem to be sufficient to initiate myelination (see Figure 
3B). 
 
The final differentiation step of oligodendrocytes has been linked to NMDA receptors, acting through 
the Akt/mTOR pathway (Li et al., 2013; Lundgaard et al., 2013). NMDA receptors are found on OPC 
processes (Káradóttir et al., 2005; Salter and Fern, 2005) and inside compact myelin sheaths 
(Káradóttir et al., 2005; Micu et al., 2006). In neurons, NMDA receptors serve as coincidence 
detectors which, due to their voltage-sensitive magnesium block, detect separate glutamatergic inputs 
converging on the cell. Once activated, NMDA receptors are far more sensitive to glutamate and more 
permeable to calcium than AMPA/kainate receptors (see Figure 2C). In a similar manner, NMDA 
receptors might be important activity-detectors in OPCs. In myelinating co-cultures, the growth 
factors neuregulin (NRG) and brain-derived neurotrophic factor (BDNF) have been shown to switch 
myelination to become regulated by neuronal activity. In this mode, differentiation and myelination 
depend on OPC NMDA receptor activation (Lundgaard et al., 2013; see Figure 3C). Inhibiting either 
neuronal activity or NMDA receptors leads to a significant reduction of myelination (Li et al., 2013; 
Lundgaard et al., 2013). Activating NMDA receptors, on the other hand, promotes myelination and 
the local production of both MBP and myelin oligodendrocyte glycoprotein (MOG) in vitro 
(Cavaliere et al., 2012; Li et al., 2013; Lundgaard et al., 2013; Wake et al., 2011). In stem cells 
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derived from the subventricular zone (SVZ), NMDA receptor activation leads to commitment to the 
oligodendrocyte lineage. As their differentiation progressed, NMDA subunits GluN1 and GluN2A 
increased while GluN2B and GluN3 decreased suggesting that maturation is matched by a differential 
expression profile of NMDA receptor composition (Cavaliere et al., 2012; see Figure 2C and Table 
1).  
 
In vivo, the role of NMDA receptors in the context of myelination is less clear. Concomitantly 
deleting the NMDA receptor subunits GluN2D and GluN3A in mice resulted in subtle myelin defects 
in myelin ultra-structure (periodicity), whereas independent deletion showed no phenotype (Micu et 
al., 2016). While this seemingly supports the hypothesis that NMDA receptors are involved in the 
terminal oligodendroglial differentiation steps, it has to be noted that in this study the knockout of the 
NMDA receptor subunits was global, thus affecting multiple cell types. On the other hand, deleting 
the compulsory subunit GluN1 exclusively in oligodendroglia (driven by PDGF-R-α, Olig2 or PLP 
promoters) had no obvious effect on myelination (De Biase et al., 2011; Guo et al., 2012), as detected 
by g-ratio (De Biase et al., 2011) and immunohistochemistry analysis (De Biase et al., 2011; Guo et 
al., 2012), albeit myelin ultrastructure was not analysed. However, in these mice an upregulation of 
calcium-permeable AMPA receptors was detected in OPCs (De Biase et al., 2011), possibly to 
compensate for the lack of NMDA receptors. Whether the mode of myelination independent of 
neuronal activity, which does not depend on NMDA receptor activation (Lundgaard et al., 2013), is 
sufficient to myelinate axons in development, or whether calcium-permeable AMPA receptors can 
compensate for the lack of NMDA receptors, is still unclear. Additionally, NMDA receptor activation 
might also be important for regulating myelin architecture or fine tuning myelin structure. 
 
Myelin and glutamate signalling  
AMPA/kainate and NMDA receptors might regulate different steps in the differentiation phase, but 
once myelination is achieved, it seems their orchestrated efforts are needed. Mature oligodendrocytes 
respond to neuronal stimulation by a calcium rise in myelin only when both AMPA and NMDA 
receptors work in concert (Micu et al., 2016). Moreover, NMDA receptor activation regulates 
mitochondria movement within the myelin sheath (Rinholm et al., 2016), presumably to provide 
energy to myelin sheaths wrapped around the most active axons and to coordinate myelin synthesis 
(Rinholm et al., 2011). This suggests that glutamate signalling may not only be important for the 
initiation and completion of differentiation, but also for myelin maintenance and plasticity. This is in 
line with studies showing that OPCs preferentially myelinate active, vesicle-releasing neurons in vitro 
(Wake et al., 2015) and in vivo (Hines et al., 2015) and that myelin sheaths wrapped around active 
neurons are more likely to be preserved (Hines et al., 2015). Myelin, therefore, may be involved in 
activity-dependent plasticity of the neuronal circuit. Myelination patterns vary significantly between 
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axons (Tomassy et al., 2014), which might reflect a myelinic way of synchronising electrical signals. 
Even small changes in myelin thickness, internodal spacing or the length of the nodes of Ranvier or 
the axonal hillock (determined by the placement of the first myelin segment) will affect the 
propagation speed of electrical signals (Pajevic et al., 2014; Ford et al., 2015). 
 
Taken together, these studies show that, depending on the microenvironment, glutamate could be one 
of the key factors regulating differentiation and myelination of oligodendroglia and might be involved 
in circuit plasticity by inducing myelin adjustments. However, the effects of glutamate are complex 
and further experiments are needed to elucidate its role in differentiation and myelination.  
 
The destructive and instructive roles of glutamate in white matter disease 
Glutamate as a regulator of myelination might not only be important for development and white 
matter plasticity, but also in the context of myelin regeneration in disease. Both beneficial and 
harmful effects of glutamate in white matter have been reported, suggesting a dual role for glutamate 
in white matter disorders. There is a variety of diseases affecting the white matter, ranging from 
genetic leukodystrophies, multiple sclerosis (MS), periventricular leukomalacia (PVL), stroke and 
traumatic injuries (reviewed by Almad et al., 2011; Goldberg and Ransom, 2003; Baltan, 2015 in this 
issue) to psychiatric disorders like schizophrenia (Flynn et al., 2003) and substance abuse (reviewed 
by Feng, 2008). Emerging hypotheses also implicate early white matter changes as a contributing 
component in neurodegenerative diseases such as dementia (including Alzheimer’s disease; Prins et 
al., 2015; O’Dwyer et al., 2011a, 2011b; Van Rooden et al., 2014; reviewed by Brickman et al., 2015) 
and associate oligodendrocyte degeneration with amyotrophic lateral sclerosis (Kang et al., 2013). 
Therefore, a better understanding of the role of glutamate in myelin disorders could have wide 
implications. 
 
Examples of the harmful side of glutamate can be seen in ischemia and inflammation in which the 
extracellular glutamate concentration can rise to excitotoxic levels (reviewed by Choi, 1994; 
Káradóttir and Attwell, 2007). As the white matter is located at the distal end of the brain vasculature 
(Duvernoy et al., 1981) it is very susceptible to changes in blood flow and oligodendrocytes 
themselves are very sensitive to oxygen and glucose deprivation, the hallmarks of stroke, hypoxia or 
vascular dementia. There are many possible sources of the excess glutamate under such conditions. 
Activated microglia can release glutamate during inflammation (Barger et al., 2007; Noda et al., 1999; 
Piani et al., 1991; Takaki et al., 2012), whilst injured neurons can release abnormal levels of 
glutamate (Mark et al., 2001) due to their high intracellular glutamate concentrations (Danbolt, 2001). 
Furthermore, astrocytes, oligodendrocytes and neurons all express glutamate transporters (Domercq et 
al., 1999; Kanai and Hediger, 1992; Kugler and Schmitt, 1999; Pitt et al., 2003; Danbolt et al., 1992; 
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reviewed by Allen et al., 2004), which can be down-regulated and therefore fail to clear extracellular 
glutamate. Glutamate transporters can also reverse, for example due to a deterioration of ionic 
gradients, often caused by a lack of energy supply, as occurs in ischemia. This leads to glutamate 
being released instead of cleared by the transporters (Kriegler and Chiu, 1993; Rossi et al., 2000; 
reviewed by Danbolt, 2001; Káradóttir and Attwell, 2007). The down-regulation of these transporters 
was observed in MS lesions concomitantly with high concentrations of extracellular glutamate 
(Lehmann et al., 2009; Pitt et al., 2003). Another source of glutamate could be the blood, especially in 
MS and other diseases where the blood-brain barrier is compromised (Minagar and Alexander, 2003), 
as the glutamate concentration in plasma is much higher than in the extracellular space of the CNS. 
Depending on the location and method used for measuring glutamate levels, the reported values vary 
considerably, ranging from 0.02 µM to 20 µM for the extracellular concentration, and from 30 µM to 
100 µM in the plasma (Hawkins, 2009; Moussawi et al., 2011; Smith, 2000).  
 
The increase in extracellular glutamate levels due to non-synaptic release from the sources described 
above can then induce cytokine production and activate immune cells promoting inflammation (see 
also Box 2). In addition, glutamate can cause excitotoxic cell death mediated by an ‘overactivation’ of 
glutamate receptors. Such an ‘overactivation’ leads to extensive calcium influx toxic to the cells and 
to sodium influx resulting in swelling and lysis of cells, which can in turn release even more 
glutamate (Choi, 1987; Káradóttir and Attwell, 2007; Trump and Berezesky, 1995). This escalating 
cycle of glutamate excitotoxicity can be blocked by using glutamate receptor antagonists, which have 
been shown to prevent ischemia-induced cell death in vivo (Mattson, 2003; Mark et al., 2001). 
 
In contrast to neurons lost due to ischemia or glutamate excitotoxicity, myelin can be regenerated. We 
have recently demonstrated that remyelination, like myelination, is regulated by neuronal activity and 
depends on glutamate release from the demyelinated axon (Gautier et al., 2015; Lundgaard et al., 
2013). This demonstrates that despite being toxic at high concentrations, glutamate also has an 
instructive role in regeneration. Remyelination is carried out by OPCs that migrate to the site of 
damage, proliferate, differentiate and wrap their processes around the demyelinated axons to form a 
new myelin sheath (see reviews in this issue by Chamberlain et al., 2016; Tognatta & Miller 2016). It 
has been shown recently that demyelinated axons upregulate presynaptic proteins in the ethidium 
bromide lesion model in rats (Gautier et al., 2015), in lysolecithin lesions in mice (Etxeberria et al., 
2010; Sahel et al., 2015) and in MS patients, and are able to form synapses with recruited OPCs 
(Gautier et al., 2015; Sahel et al., 2015). These OPCs express AMPA/kainate receptors and, at later 
stages, also NMDA receptors (Gautier et al., 2015). Blocking either neuronal activity, vesicular 
release of glutamate, AMPA/kainate or NMDA receptors in the lesion inhibits remyelination (Gautier 
et al., 2015; Li et al., 2013; Lundgaard et al., 2013). The time course of glutamate receptor expression 
in OPCs in demyelinated lesions is in line with the described roles of AMPA and NMDA receptors 
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during myelination: AMPA receptors are important in the early phase of OPC proliferation and initial 
differentiation, whereas NMDA receptors are expressed at later time points and are needed for myelin 
sheath formation (Gautier et al., 2015; Li et al., 2013; Lundgaard et al., 2013). Similar to myelination, 
the effects of NMDA receptor activation on remyelination seem to be mediated via the Akt/mTOR 
pathway (Li et al., 2013; Lundgaard et al., 2013) and as in development (Mensch et al., 2015) it is 
predominantly the (re)myelination of small diameter axons that depends on neuronal activity and 
glutamate. Larger calibre axons still become myelinated when vesicular release of neurotransmitters is 
blocked (Mensch et al., 2015) and are also remyelinated even when activity or synaptic signalling are 
inhibited (Gautier et al., 2015).  
 
The contradictory effects of glutamate in white matter disease, with excitotoxicity on the one hand 
and the promotion of remyelination on the other, become apparent in MS. In this autoimmune disease 
spontaneous remyelination can occur in patients. However, with ageing and after cycles of 
demyelination and remyelination, symptomatically mirrored by phases of relapse and remission, 
remyelination will ultimately decline resulting in chronically demyelinated axons (Franklin, 2002). 
The failure of remyelination is a major contributing factor to the accumulation of neuronal loss and 
disability (reviewed by Bjartmar et al., 2003). Therefore, as glutamate signalling regulates 
remyelination, enhancing this communication might be a promising therapeutic approach in these 
cases.  
 
However, the pathogenesis of MS is complex and influenced by many factors (see reviews in this 
issue Chamberlain et al., 2016; Sedel et al., 2016; Tognatta and Miller, 2016). Inflammation, for 
example, has been linked to the initial attack on the myelin sheath and to neurodegeneration seen in 
MS patients. Inflammation is high in the initial phase of MS and since cell death occurs 
predominantly in highly inflamed areas, it has been suggested that excess inflammation causes 
neuronal loss (Trapp et al., 1998). Inflammation might be the primary cause of neurodegeneration 
occurring independent of oligodendrocyte damage, as neuronal loss can be observed in normal-
appearing white matter in MS patients (Evangelou et al., 2000). This inflammation-induced 
neurodegeneration might be due to disruptions of glutamate release and clearance that are documented 
in MS tissue (reviewed by Frigo et al., 2012; Tilleux and Hermans, 2007). Glutamate concentrations 
are significantly increased in the cerebrospinal fluid, in acute brain lesions and in normal appearing 
white matter of MS patients (Srinivasan et al., 2005; Stover et al., 1997). In addition to neuronal 
degeneration due to pathological increases in glutamate, there might also be direct detrimental effects 
on oligodendrocytes, as perfusion of kainate into the optic nerve was shown to generate MS like 
demyelinated lesions (Matute et al., 1997). 
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Based on these observations, reducing glutamate levels seems a sensible therapeutic strategy. Indeed, 
the FDA-approved antibiotic ceftriaxone increased the expression of the glutamate transporter GLT-1 
(EAAT2) in vitro, provided neuroprotection in vivo in disease models encompassing excessive 
glutamate levels (Rothstein et al., 2005; but see Melzer et al., 2008) and alleviated clinical symptoms 
in experimental autoimmune encephalomyelitis (EAE) (Melzer et al., 2008; Ramos et al., 2010). 
Similarly, blocking AMPA signalling with NBQX reduced disease severity in EAE (Ohgoh et al., 
2002; Pitt et al., 2000; reviewed by Smith, 2000). Remarkably, NBQX administration prevented EAE-
related changes in glutamate transporter expression, indicating that AMPA receptor activation 
regulates transporter expression. It is not clear, however, if the observed beneficial effects are due to a 
protection of oligodendrocytes or neurons, or both. The primary neuronal loss in EAE might be too 
rapid and substantial to reveal any secondary neurodegeneration that would occur in MS due to 
impaired oligodendrocyte survival. In addition to AMPA receptor inhibitors, also NMDA receptor 
antagonists have been tested in EAE and MS patients: Memantine and amantadine improved 
neurological symptoms in EAE and memantine and MK801 mediated neuroprotection in experimental 
autoimmune optic neuritis (Sühs et al., 2014; Sulkowski et al., 2013; Wallström et al., 1996). 
Amantadine is prescribed against fatigue, a clinical hallmark of MS, but whether its effect is mediated 
via NMDA receptor inhibition is unclear as the drug can affect numerous other pathways, such as 
dopamine signalling (Scatton et al., 1970). Memantine trials for MS were terminated because of 
reversible neurological side effects (https://clinicaltrials.gov/ct2/show/NCT00638833), but it is 
approved for Alzheimer’s disease where it is thought to protect neurons by preventing glutamate 
excitotoxicity (Lipton, 2006).  
 
The seemingly contradicting findings on glutamate being potentially toxic, but also essential for 
instructing myelin regeneration, could be explained by the need for a localised and timed 
communication between axons and OPCs, rather than a general sustained glutamate release that 
increases the extracellular glutamate concentration to toxic levels. Such a pathological increase in 
overall glutamate levels might disturb the synaptic signalling required for myelin regeneration and 
instead stimulate non-synaptic glutamate signalling pathways, thus promoting, for example, the 
activation of immune cells and inflammation – which could exacerbate the damage.  
 
Conclusions  
It is becoming evident that the source of glutamate or the mechanism of its release, whether it is 
activity-dependent vesicular release (i.e. fast), or non-vesicular release (i.e. slow) may convey 
different regulatory functions for oligodendrocyte proliferation, differentiation and myelination, both 
during development and in disease. This combined with the fact that oligodendrocytes express 
different glutamate receptor types and subunits at different stages during development (Table 1), 
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suggests that glutamate might have different effects depending on the signalling mechanisms at 
different timepoints. Thus, the seemingly conflicting roles that have been identified may reflect 
different mechanisms of ‘release’ (or administration of glutamate in in vitro studies) as well as 
differential timepoints of oligodendrocyte lineage cell development or the age of the animal in use. 
Hence, to fully understand the role of glutamate in oligodendrocyte biology, it needs to be studied in 
the context of release and the age and developmental stage of the oligodendrocyte lineage cell.  
 
Given the increasing body of evidence found for white matter plasticity and de novo myelination in 
adulthood, it is important to expand our knowledge of glutamate signalling in the context of 
myelination. This will also deepen our understanding of its role in disease and help to develop new 
therapies that prevent glutamate excitotoxicity, without curtailing the beneficial effects of glutamate 
signalling needed for myelin regeneration.  
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Figure legends: 
 
Figure 1: Multiple ways of glutamate release 
(A-D) Vesicular glutamate can be released in an activity- and canonical SNARE-dependent (A, B; 
canonical) or -independent way (C, D; non-canonical). Both types of vesicular release can occur at 
synapses in the mature CNS. However, they can also be observed in absence of a postsynaptic density 
for example prior to synapse formation in development when growing axons release 
neurotransmitters. This vesicular release is thought to guide the postsynaptic dendrite to form the final 
synaptic contact, a mechanism possibly copied by OPCs to form the axon-OPC synapse. Although 
depicted here as axonal release, vesicular release of glutamate can also be observed in non-neuronal 
cells, such as astrocytes. Furthermore, there is non-vesicular release of glutamate (E) from various 
sources e.g. microglia, astrocytes or injured cells, from the blood stream or from reversal of glutamate 
transporters for example in cells that suffer from energy shortage in ischemia. 
The mode of glutamate release might differentially affect the downstream signalling in 
oligodendroglia as the glutamate concentration and the location and timing of glutamate receptor 
activation differ. To what extent these different modes of glutamate release play a role for OPC 
migration, proliferation, differentiation and myelination in vivo is not yet fully understood. 
 
 
 
Figure 3: Effects of glutamate on OPC proliferation, differentiation and myelination 
Generally, glutamate seems to inhibit proliferation in OPCs (see text for exceptions) (A). mGluR 
activation promotes cell maturation and differentiation, whilst activation of AMPA/kainate receptors 
inhibits differentiation (B). When myelination is carried out in the activity-dependent mode, 
glutamate was shown to promote the expression of myelin proteins and myelination through NMDA 
receptors (C).  
 
 
Table legend: 
 
Tab. 1: Ionotropic glutamate receptor expression in oligodendrocytes and OPCs 
Overview of RNA and protein expression of the different ionotropic glutamate receptor subunits in 
oligodendrocytes and OPCs. Data obtained from cell lines were not included in the table. References 
and the species from which the data were obtained are listed below.  
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[1] Patneau et al., 1994 (rat); [2] Li and Stys, 2000 (rat); [3] Matute et al., 1997 (rat); [4] Itoh et al., 
2002 (rat); [5] Cahoy et al., 2008 (mouse); [6] Zhang et al., 2014 (mouse); [7] Salter and Fern, 2005 
(mouse); [8] Garcia-Barcina and Matute, 1996 (bovine); [9] Micu et al., 2006 (rat); [10] Káradóttir et 
al., 2005 (rat); [11] Burzomato et al., 2010 (rat); [12] Lundgaard et al., 2013 (rat); [13] Piña-Crespo et 
al., 2010 (rat); [14] Kukley and Dietrich, 2009 (mouse); [15] Alix and Fern, 2009 (rat); [16] Wang et 
al., 1996 (rat); [17] Hamilton et al., 2010 (mouse); [18] Liu et al., 2002 (rat); [19] Guo et al., 2012 
(mouse); [20] Hossain et al., 2014 (rat); [21] Bakiri et al., 2008 (rat); [22] Newcombe et al., 2008 
(human); [23] Rosenberg et al., 2003 (rat); [24] Harlow et al., 2015 (mouse); [25] Yoshioka et al., 
1995 (rat); [26] Brand-Schieber and Werner, Neurosci Lett, 2003 (GluK5 in mouse, not in rat; GluA4 
in rat, not in mouse); [27] Fogarty et al., 2000 (rat); [28] Chew et al., 1997 (rat, GluA1 and GluK3 in 
presence of bFGF/PDGF); [29] Gallo et al, 1994 (rat); [30] Deng et al., 2006 (rat); [31] Ong et al., 
1996 (rat); [32] Li et al., 2013 (rat); [33] Gudz et al., 2006 (rat); [34] Xiao et al., 2013 (rat) 
 
Tab. 1: Ionotropic glutamate receptor expression in oligodendrocytes and OPCs 
 AMPA Receptor Subunits  Kainate Receptor Subunits  NMDA Receptor Subunits 
Gl
uA
1 
RNA 
OPC Low [1][4][5][6][28]/Yes [25] 
Gl
uK
1 
RNA 
OPC Yes [5][6][25] /No [1][28] 
Gl
uN
1 
RNA 
OPC Yes [5][6][16] 
Oligo. Low [4][5][6]/Yes [25] /No [3] Oligo. Yes/Low [5][6][25] /No [3] Oligo. Low [5][6][19] 
Protein 
OPC Yes [18][20][28][30] /No/Low [4][24] 
Protein 
OPC No [14] 
Protein 
OPC Yes [10][16][32][34] 
Oligo. No [2][3][4][20] /Yes [22] Oligo. N/A Oligo. Yes [9][10][11][13][15][21][32] /Low [19] 
Gl
uA
2 
RNA 
OPC Yes/High [1][4][5][6][25][28] 
Gl
uK
2 
RNA 
OPC Yes [1][5][6][25][28] 
Gl
uN
2A
 RNA OPC Low 
[5] /No [6][16] 
Oligo. Yes/High [4][5][6][25] /No [3] Oligo. Yes [3][5][6][25] Oligo. Low [5] /No [6] 
Protein 
OPC Yes [4][18][20][23][24][30][33] 
Protein 
OPC N/A 
Protein 
OPC Yes [32] /No [12] 
Oligo. Yes [4][22] /No [2] /Low [20] Oligo. N/A Oligo. Yes [19][32] /No [12] 
Gl
uA
3 
RNA 
OPC Yes/High [1][4][5][6][25][28] 
Gl
uK
3 
RNA 
OPC Yes [1][6][25][28] 
Gl
uN
2B
 RNA OPC Low 
[5] /No [6][16] 
Oligo. Yes/High [3][4][5][6][25] Oligo. Yes [3][6][25] Oligo. Low [5] /No [6] 
Protein 
OPC Yes [4][24][30] 
Protein 
OPC N/A 
Protein 
OPC Yes [32] 
Oligo. Yes [2][4] Oligo. N/A Oligo. Yes [32] 
Gl
uA
4 
RNA 
OPC High [1][4][5][6][28][29] /No [25] 
Gl
uK
4 
RNA 
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Glutamate - too common to be exciting!
Early in the 20th century, it was found that glutamate (also known as L-glutamate or 
glutamic acid) occurred in high concentrations in the brain. At the time, outside its role 
as a building block for proteins, glutamate was thought to be predominantly involved in 
energy metabolism – it is a metabolic intermediate of the citric acid cycle and involved 
in diverse metabolic processes such as protein synthesis, glycolysis and 
gluconeogenesis and forms part of the nitrogen-urea cycle. It is enriched in protein 
containing food, but can also be synthesised in the body. 
In the 1950s, a series of findings argued that glutamate was a neurotransmitter in the 
CNS, but this concept was faced with great scepticism. As glutamate is such an 
abundant amino acid it did not fit the description of a neurotransmitter at the time. It was 
not until several decades later that the role of glutamate for synaptic transmission was 
established (Watkins, 1972; Watkins and Jane, 2006). Today, glutamate is known to be 
the major excitatory neurotransmitter in the central and enteric nervous system of  
mammals (Kirchgessner, 2001).
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Box 2
Canonical and non-canonical glutamate signalling
Glutamate signalling in the CNS is generally thought to be mediated by activity- and canonical 
SNARE-dependent vesicular release at the pre-synapse (i.e canonical glutamate signalling). 
However, glutamate as a signalling molecule and the expression of glutamate receptors are neither 
limited to the nervous system nor to organisms which have a nervous system. Non-canonical 
glutamate signalling is characterised by activity- and canonical SNARE-independent release of 
glutamate and can occur both at the synapse as well as outside synapses (Manent et al., 2005). 
Non-canonical glutamate signalling in the CNS regulates:  
•    Migration patterns of immature hippocampal pyramidal neurons (Manent et al., 2005) 
•    Proliferation of stem cells of the SVZ via metabotropic glutamate receptor (mGluR5) signalling 
     (mGluR5 expression precedes synaptogenesis) (Di Giorgi-Gerevini et al., 2005) 
•    Retinal progenitor cell proliferation during a time in development when synapses have not 
     yet formed (Martins et al., 2006) 
•    Motility (Rzeski et al., 2001) and proliferation (Kalariti et al., 2005) of tumour cells 
•    Dendritic arbour formation and directs dendrites to presynaptic terminals prior to synapse 
     formation (Andreae and Burrone, 2015) 
•    Commitment to the neuronal fate and increases the differentiation rate into GABAergic 
     neurons through mGluR activation in embryonic stem cells (Sarichelou et al., 2008) 
•    Synapse stabilisation (Kaeser and Regehr, 2014 )
Non-canonical neurotransmitter signalling in non-neuronal tissue 
(see also reviews by Gill and Pulido, 2001; Hinoi et al., 2004; Julio-Pieper et al., 2011)
•    Bone: Non-synaptic glutamate signalling promotes differentiation of osteoblast precursors into 
     osteoblasts, boosts osteoblast survival and leads to cell maturation (Genever and Skerry, 
     2001; Lin et al., 2008)
•    Blood: Differentiation of megakaryocytes is regulated by non-synaptic activation of NMDA 
     receptors expressed by megakaryocytes (Genever et al., 1999)
•    Hormonal release: Non-canonical glutamate signalling regulates hormonal release in the 
     pineal gland and the pancreas (Storto et al., 2006)
•    Immune system: Glutamate signalling activates T-cells as well as lymphocyte cytokine 
     production and survival in the mammalian immune response (Boldyrev et al., 2004; 
     Chiocchetti et al., 2006; Pacheco et al., 2004)
•    Cancer: Glutamate signalling, via NMDA receptors, promotes tumour growth and invasion (Li 
     and Hanahan, 2013)
Non mammalian non-canonical glutamate signalling
Glutamate signalling and glutamate receptor expression can be found in all living organisms, 
even in primitive ones lacking a nervous system and in earliest marine metazoans (Forde and 
Lea, 2007). In prokaryotes and eukaryotes, glutamate can serve as a chemotactic signal and 
trigger feeding-related locomotion (Bakker et al., 2007; Bellis et al., 1991; see review by Forde 
and Lea, 2007). In Arabidopsis plants, glutamate receptors are expressed in a higher density in 
the roots (Chiu et al., 2002) which respond to glutamate with rapid membrane depolarisation 
(Dennison and Spalding, 2000), leading to root growth, altered root tip morphology and branching 
(similar perhaps to axonal growth cone and dendritic spine growth) (Sivaguru et al., 2003; 
Walch-Liu et al., 2006). Glutamate may also be involved in the defence response as it regulates 
the expression of defence genes in plants (see review by Forde and Lea, 2007).
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